Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Calcineurin–NFAT docking interface is a specialized protein-protein interaction site essential for the calcium-dependent signaling pathway that governs T-cell activation. Calcineurin, a serine/threonine phosphatase, recognizes and binds to the Nuclear Factor of Activated T-cells (NFAT) through two distinct conserved motifs: the high-affinity PxIxIT motif and the C-terminal LxVP motif (PubMed: 11430833, 17412991). Upon binding, calcineurin dephosphorylates multiple residues on NFAT, exposing its nuclear localization signal and allowing it to translocate into the nucleus to initiate the transcription of pro-inflammatory cytokines like IL-2 (UniProt: P17544). While classic inhibitors like Cyclosporine A and Tacrolimus effectively block this pathway by forming complexes that sterically hinder the active site, they often lead to off-target toxicity because they inhibit calcineurin's phosphatase activity toward all substrates (PubMed: 19144315). Modern therapeutic strategies focus on small molecules or peptides, such as the VIVIT peptide, that specifically compete for the docking interface to selectively inhibit NFAT activation without disrupting other vital calcineurin-mediated processes (PubMed: 11430833). This interface represents a high-value target for developing more precise immunosuppressive and anti-inflammatory agents with reduced side-effect profiles.
Inhibition of protein-protein interaction between calcineurin and NFAT, preventing NFAT dephosphorylation and subsequent nuclear translocation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcineurin–Nuclear factor of activated T-cells docking interface (Cn–NFAT interface).